HTB

CROI 15 (Retrovirus) 2008

15th Conference on Retroviruses and Opportunistic Infections, Boston, 2-6 February 2008

The unmet need for contraception services for women receiving ART

Valacyclovir decreases plasma and genital viral loads in HSV-2/HIV-1 co-infected women

HPV genotypes in HIV-positive women in Zimbabwe and Uganda

Low rates of MTCT in UK and Ireland

15th Conference on Retroviruses and Opportunistic Infections, Boston, 2-6 February 2008

Immediate HAART reduces death and AIDS progression over 48 weeks in patients with acute OIs

Utility of routine viral load, CD4 count and clinical monitoring among HIV-positive adults in rural Uganda

Implementation of more complex regimens for prevention of mother-to-child transmission of HIV in Rwanda

The estimated cost of switching from d4T to TDF in South Africa

Gender differences in viral load by CD4 count in men and women

Immune reconstitution inflammatory syndrome in young children initiating ART

Complications with BCG vaccination in HIV-positive and negative infants: CHER Study

The association between clinical characteristics and HIV-infection in very young infants

Safety and efficacy of boosted darunavir in treatment-experienced children and adolescents at 24 weeks

Responses to atazanavir-containing HAART in treatment-naive children in South Africa

Initial growth, CD4, and viral load responses to HAART in Ugandan compared to UK/Irish HIV-positive children

Paediatric pharmacokinetic studies

A pilot study of three treatment strategies for HIV-positive infants

15th Conference on Retroviruses and Opportunistic Infections, 2-6 February 2008, Boston

Atazanavir/r vs lopinavir/r in treatment-naive patients: 48 week results

Baseline inflammation and coagulation markers and changes over four weeks during a treatment interruption are strongly linked to HIV viraemia and risk of mortality

Restarting treatment after an interruption reduces the risk of serious events but CD4 recovery falls short of baseline levels

Very low rate of MTCT in women on HAART in UK and Ireland who achieve viral suppression

Predictors of mother to child transmission among women initiating HAART in pregnancy in a South African cohort

Maternal and infant outcomes from the DREAM programme

Nevirapine-resistant HIV present in the latent reservoir following single-dose nevirapine for MTCT prevention

Tenofovir plus FTC reduce NNRTI resistance following single dose nevirapine

Response to treatment after single dose NVP exposure in women

Response to treatment after single dose NVP exposure in infants

Other studies looking at birth outcomes

Infant prophylaxis for postnatal transmission

Antiretroviral drug concentrations in breast milk and breastfeeding infants

Maternal breastfeeding prophylaxis

Risk factors for breastfeeding transmission

UK cohort reports sexual HCV reinfection in at least 5% HIV-positive gay men following sustained response to treatment

MELD score predictive of pre-transplant mortality in HCV coinfected patients

Does abacavir decrease SVR rates with HCV treatment?

No effect of interferon maintenance therapy on fibrosis progression in non-responders

Stem cell transplant from HLA-matched CCR5-delta 32 deleted donor suppresses viraemia in recipient for 8 months without HAART

Risk factors for AIDS-defining and non AIDS-defining cancers

CROI 2008 – 12 key areas of research: non-technical summary of 25 studies and presentations

15th Conference on Retroviruses and Opportunistic Infections, 2-6 February 2008, Boston

Increased risk of myocardial infarction associated with abacavir and ddI

Position statement by the D:A:D steering committee